Trulieve Commemorates Georgia Medical Cannabis Launch with First Sale

Rhea-AI Summary

Trulieve (NYSE: TRLV) marked Georgia’s expanded medical cannabis program with a ceremonial first sale at its Marietta dispensary. New law SB 220 allows flower and vaporization products for patients 21+ and broadens qualifying conditions. Trulieve is also supplying products to over a dozen licensed independent pharmacies statewide.

Positive

• Georgia law SB 220 adds flower and vaporization products for eligible medical patients
• Trulieve begins supplying medical cannabis to over a dozen Georgia independent pharmacies
• All six Georgia locations host launch events, patient consultations, and product education

Negative

• None.

News Market Reaction – TRLV

-2.95%

2 alerts

-2.95% Session close to close

$1.94B Market Cap

0.4x Rel. Volume

In the Jul 1 session, TRLV declined 2.95%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Georgia’s broadened medical cannabis access, including pharmacy distrib...

Analysis

This announcement highlights Georgia’s broadened medical cannabis access, including pharmacy distribution and six in-state locations. With shares about 20.08% below the 52-week high and low short interest, execution in Georgia remains a key factor to watch.

Key Figures

Law signed date: May 12, 2026 Patient age minimum: 21 years Price change: 6.39% +5 more

8 metrics

Law signed date May 12, 2026 Georgia SB 220 signature expanding medical cannabis program

Patient age minimum 21 years Minimum age for access to flower and vaporization products in Georgia

Price change 6.39% 24h move prior to/around Georgia expansion news

52-week high distance -20.08% Current price vs. 52-week high before this news

52-week low distance 24.12% Current price vs. 52-week low before this news

Relative volume 0.65x Today’s volume vs. 20-day average prior to this news

Georgia locations 6 locations Trulieve Georgia stores hosting launch-day events

Initial pharmacy partners Over a dozen Independent pharmacies in Georgia receiving Trulieve products

Historical Context

1 past event · Latest: 2026-06-26 (Neutral)

Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
2026-06-26	Insider trading plan	Neutral	+2.8%	CEO signaled intent to terminate existing automatic share disposition plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Too few prior news-linked reactions are available to establish a reliable pattern.

Key Terms

schedule iii, dea registration

2 terms

schedule iii regulatory

"Following federal rescheduling of medical marijuana to Schedule III in April,"

A Schedule III classification is a regulatory category for drugs and substances that have a recognized medical use but a moderate risk of dependence or abuse, placing them between higher-risk controlled drugs and over-the-counter medicines. For investors, this matters because it shapes how a product can be manufactured, prescribed, marketed and distributed — affecting potential sales, regulatory hurdles, labeling requirements and legal exposure in the market; think of it as a middle level of control that influences commercial access and compliance costs.

dea registration regulatory

"pharmacies in Georgia with state licensure and DEA registration may sell medical cannabis"

A DEA registration is a federal license from the U.S. Drug Enforcement Administration that allows a business or individual to legally manufacture, distribute, prescribe, or dispense drugs that are regulated for potential abuse. For investors it signals whether a company is legally authorized to handle important prescription medicines and is meeting strict safety and reporting rules, much like a business needing a special permit to sell alcohol — lack of it can block revenue or trigger enforcement risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Expanded medical cannabis program broadens patient access in dispensaries and pharmacies

TALLAHASSEE, Fla., July 1, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S, today announced it commemorated the expansion of Georgia's medical cannabis program with a ceremonial first sale this morning at its Marietta location.

The first sale, purchased by retired Army veteran Desi Cleveland, included the Roll One Clutch All in One vape and Modern Flower whole flower — both available for the first time in Georgia — alongside his trusted Trulieve RSO Troches and Momenta Topical Cream.

"I served my country and came home with injuries that affect me every single day. For years, the options I had weren't enough — or came with costs I wasn't willing to pay," said Desi Cleveland, Army veteran from Columbus. "Having access to a vaporized product that provides fast-acting relief when I need it most – alongside the other administration methods I already trust – is something I've been waiting for. Today marks a big step forward for veterans in Georgia."

"Putting Georgia's Patients First Act," or Senate Bill 220, was signed into law by Governor Brian Kemp on May 12, 2026, significantly expanding Georgia's medical cannabis program. The law adds flower and vaporization products for patients 21 and older, expands qualifying conditions to include lupus, HIV, and inflammatory bowel disease, and removes the "end-stage" restrictions that previously limited access for patients living with conditions such as cancer, multiple sclerosis, and Parkinson's disease.

"We are thrilled to provide Georgia patients with a wider variety of products at our dispensaries and independent pharmacies," said Trulieve's Chief Executive Officer Kim Rivers. "We applaud Governor Kemp and the state legislature for recognizing the patient need and addressing it with SB 220."

Following federal rescheduling of medical marijuana to Schedule III in April, independent pharmacies in Georgia with state licensure and DEA registration may sell medical cannabis products to qualified patients. Trulieve has begun providing products to over a dozen pharmacies and expects to expand pharmacy distribution this summer.

"We are proud to partner with Trulieve to offer their trusted products to our patients," said Parth Patel, PharmD, owner of Bonaire Pharmacy. "Pharmacists are trusted healthcare providers, and being able to provide medical cannabis alongside our patients' other medications is a natural extension of the care we already deliver, in their convenient, neighborhood pharmacy setting."

All six Trulieve Georgia locations will host launch-day events featuring patient consultations, product specials, giveaways, and education on program enrollment and new products. For more information on Trulieve's Georgia store locations click here. Follow us on Instagram @Trulieve.GA.

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established medical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia. Driven by a core mission to expand access to cannabis, Trulieve serves customers with innovative, high-quality branded products and exceptional experiences. With scaled operations in attractive markets and targeted expansion through its hub strategy, Trulieve is poised for accelerated growth. Trulieve is listed on the NYSE under the symbol TRLV. For more information, please visit Trulieve.com.

Facebook: @Trulieve   
Instagram: @Trulieve
X: @Trulieve

Investor and Media Contact
Christine Hersey, Chief Corporate Affairs and Strategy Officer
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-commemorates-georgia-medical-cannabis-launch-with-first-sale-302814823.html

SOURCE Trulieve Cannabis Corp.

FAQ

What did Trulieve (NYSE: TRLV) announce about the Georgia medical cannabis launch on July 1, 2026?

Trulieve announced a ceremonial first sale marking Georgia’s expanded medical cannabis program at its Marietta location. According to Trulieve, this celebrates broader product access, including flower and vaporization options, for qualified patients aged 21 and older across the state.

How does Georgia Senate Bill 220 affect medical cannabis patients and Trulieve (TRLV)?

Senate Bill 220 significantly expands Georgia’s medical cannabis program. According to Trulieve, it allows flower and vaporization products for patients 21+, adds conditions like lupus, HIV, and inflammatory bowel disease, and removes “end-stage” limits for illnesses such as cancer, multiple sclerosis, and Parkinson’s disease.

Can independent pharmacies in Georgia now sell Trulieve (TRLV) medical cannabis products?

Yes. Following federal rescheduling to Schedule III, licensed independent pharmacies in Georgia may sell medical cannabis to qualified patients. According to Trulieve, it has begun providing products to over a dozen pharmacies and plans to expand pharmacy distribution during the summer.

What products were included in Trulieve’s first expanded medical cannabis sale in Georgia?

The first sale featured Roll One Clutch All in One vape and Modern Flower whole flower, available first-time in Georgia. According to Trulieve, the purchase also included its RSO Troches and Momenta Topical Cream, reflecting multiple administration methods for patients.

How many Trulieve (TRLV) locations in Georgia are involved in the medical cannabis launch events?

All six Trulieve Georgia locations are participating in launch-day events. According to Trulieve, these events include patient consultations, product specials, giveaways, and education on program enrollment and new products to support patients adapting to the expanded medical cannabis options.

What new qualifying conditions are covered under Georgia’s expanded medical cannabis law relevant to Trulieve patients?

The expanded law adds lupus, HIV, and inflammatory bowel disease as qualifying conditions. According to Trulieve, it also removes “end-stage” restrictions for conditions like cancer, multiple sclerosis, and Parkinson’s, enabling more patients to access its medical cannabis products in Georgia.